Stay updated with breaking news from Social Avoidance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 *$44.4 million in cash and cash... | May 16, 2023
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 13, 2023
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 12, 2023
Certain personality traits may be linked to bad breath.
10.08.2022 - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with ...